Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | ST6GAL1 | P15907 | 12/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citicoline SCHEMBL667104 | 0.96 | TSHR (0.84) | TSHRGLAST6GAL1L3MBTL1P2RY2 | |
| Citicoline SCHEMBL30969948 | 0.95 | TSHR (0.82) | TSHRGLAST6GAL1L3MBTL1P2RY2 | |
| Citicoline SCHEMBL221081 | 0.92 | TSHR (0.73) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL4311534 | 0.92 | TSHR (0.76) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL50799 | 0.92 | TSHR (0.73) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL25411862 | 0.92 | TSHR (0.76) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL31413926 | 0.92 | TSHR (0.73) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL31554836 | 0.92 | TSHR (0.73) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL19347200 | 0.92 | TSHR (0.72) | TSHRGLAST6GAL1P2RY2P2RY4 | |
| Citicoline SCHEMBL21906414 | 0.90 | TSHR (0.70) | TSHRGLAST6GAL1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57179115-A | — | — | None | — | — | JP | disclosed |
| JP-62012794-A | — | — | None | — | — | JP | disclosed |
| CN-117402198-A | Citicoline salt and preparation method and application thereof | 辽宁科硕营养科技股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-2322187-B1 | Use of uridine in combination with choline for the treatment of memory disorders | MASSACHUSETTS INST TECHNOLOGY (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2329829-B1 | Use of uridine in combination with choline for the treatment of neurological disorders | MASSACHUSETTS INST TECHNOLOGY (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2145627-B1 | Use of uridine in combination with choline for the treatment of mood and emotional disorders | MASSACHUSETTS INST TECHNOLOGY (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2329829-A2 | Use of uridine in combination with choline for the treatment of memory disorders | Massachusetts Institute of Technology (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2322187-A2 | Use of uridine in combination with choline for the treatment of memory disorders | Massachusetts Institute of Technology (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2145627-A1 | Use of uridine in combination with choline for the treatment of memory disorders | Massachusetts Institute of Technology (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-1870103-B1 | Use of uridine in combination with choline for the treatment of memory disorders | MASSACHUSETTS INST TECHNOLOGY (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1140104-B1 | TREATMENT OF ALZHEIMER'S DISEASE BY INCREASING CYTIDINE LEVELS IN VIVO | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-09-26 | — | — | EP | disclosed |
| US-6989376-B2 | Methods for increasing blood cytidine and/or uridine levels and treating cytidine-dependent human diseases | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20030180249-A1 | Dosage forms for hygroscopic active ingredients | KHANNA SATISH CHANDRA (CH) | 2003-09-25 | — | — | US | disclosed |
| EP-1346732-A2 | Dosage forms for hygroscopic active ingredients | ROHM AND HAAS COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20020028787-A1 | Nervous system disorders; administering exogenous uridine compound | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-07 | — | — | US | disclosed |
| EP-1140104-A1 | METHODS FOR INCREASING CYTIDINE LEVELS IN VIVO AND TREATING CYTIDINE-DEPENDENT HUMAN DISEASES | Massachusetts Institute of Technology (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000006174-A1 | METHODS FOR INCREASING CYTIDINE LEVELS IN VIVO AND TREATING CYTIDINE-DEPENDENT HUMAN DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-02-10 | — | — | WO | disclosed |
| JP-S6212794-A | NOVEL CYTIDINE PHOSPHOCHOLINE SALT ESPECIALLY SUITABLE FOR ORAL USE | BIORESEARCH SPA | 1987-01-21 | — | — | JP | disclosed |
| JP-S57179115-A | MEDICINAL COMPOSITION CONTAINING CYTIDINE PHOSPHOCHOLINE OR SALT FOR ORAL ADMINISTRATION | MAADE ITARIAANA ETSUSE ERURE E | 1982-11-04 | — | — | JP | disclosed |
| US-4203893-A | LYSINE RESIDUES OF PROTEINS, AMINOPOLYSACCHARIDES, SYNTHETIC PEPTIDES AND BACTERIASL BODIES | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 1980-05-20 | — | — | US | disclosed |